ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021
Microfluidic and Nanofluidic Intracellular Delivery.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 104 citations in OpenAlex.
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- LED-Modulated Plasmoporation for Highly Efficient Intracellular Cargo Delivery to Suspension Cells.Nano letters · 2026Article
- Exploiting Device Deformability for Fluid and Particle Manipulation.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Parallelized droplet microfluidic mechanoporation enables robust and clogging-resistant intracellular gene delivery.Microsystems & nanoengineering · 2026Article
- Microfluidics for cell therapy and manufacturing in oncology and regenerative medicine.Lab on a chip · 2026Review
- Precision acoustofluidics for high-throughput mechanobiology in suspension cells.Science advances · 2026Article
- Engineering Organ Conformality for Precise Intracellular Delivery.Research (Washington, D.C.) · 2026Article
- Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment.Journal of extracellular vesicles · 2025Article
- High-throughput Generation of Collagen Microbeads for Extracellular Vesicle Production and Therapeutic Delivery.Advanced materials technologies · 2025Article
- Extracellular vesicle-mediated gene editing for the treatment of nonsyndromic progressive hearing loss in adult mice.Science translational medicine · 2025Article
- Subnanometer Interfacial Hydrodynamics: Spatially Resolved Viscosity and Surface Friction.Nano letters · 2025Article
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- Transfection Technologies for Next-Generation Therapies.Journal of clinical medicine · 2025Review
- Microfluidic Platforms for Ex Vivo and In Vivo Gene Therapy.Biosensors · 2025Review
- Insights to Resistive Pulse Sensing of Microparticle and Biological Cells on Microfluidic Chip.Biosensors · 2025Review
- Small Extracellular Vesicles in Neurodegenerative Disease: Emerging Roles in Pathogenesis, Biomarker Discovery, and Therapy.International journal of molecular sciences · 2025Review
- High-Throughput Microfluidic Electroporation (HTME): A Scalable, 384-Well Platform for Multiplexed Cell Engineering.Bioengineering (Basel, Switzerland) · 2025Article
- Geometric determinants of sinterless, low-temperature-processed 3D-nanoprinted glass.Microsystems & nanoengineering · 2025Article
- Advancing Allogeneic NK Cell Immunotherapy through Microfluidic Gene Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Preliminary Study on Sensor-Based Detection of an Adherent Cell's Pre-Detachment Moment in a MPWM Microfluidic Extraction System.Sensors (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Innate cell function can be artificially engineered and reprogrammed by introducing biomolecules, such as DNAs, RNAs, plasmid DNAs, proteins, or nanomaterials, into the cytosol or nucleus. This process of delivering exogenous cargos into living cells is referred to as intracellular delivery. For instance, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing begins with internalizing Cas9 protein and guide RNA into cells, and chimeric antigen receptor-T (CAR-T) cells are prepared by delivering CAR genes into T lymphocytes for cancer immunotherapies. To deliver external biomolecules into cells, tools, including viral vectors, and electroporation have been traditionally used; however, they are suboptimal for achieving high levels of intracellular delivery while preserving cell viability, phenotype, and function. Notably, as emerging solutions, microfluidic and nanofluidic approaches have shown remarkable potential for addressing this open challenge. This review provides an overview of recent advances in microfluidic and nanofluidic intracellular delivery strategies and discusses new opportunities and challenges for clinical applications. Furthermore, key considerations for future efforts to develop microfluidics- and nanofluidics-enabled next-generation intracellular delivery platforms are outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.